BioAlliance Pharma reacquires the rights to Loramyc in Europe
BioAlliance Pharma SA announced the termination of the licensing agreement signed in 2007 with SpeBio (a joint venture with SpePharm). The exclusive license in European Union countries other than France covered the distribution of Loramyc®, a muco-adhesive buccal tablet for treating in oropharyngeal candidiasis, a type of infected mucositis, in immunodepressed patients.
BioAlliance Pharma has initiated legal proceedings in Paris against SpeBio for violation of the latter’s contractual obligations and in order to obtain appropriate compensation for losses suffered as a result of delays in commercialization and sale of Loramyc®.
BioAlliance Pharma is confident in ensuring the continued Europe-wide commercialization of Loramyc® directly in selected countries and through specialist oncology partners in other countries.
Most read news
Organizations
Other news from the department politics & laws

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.